ARCH-backed HI-Bio touts ear­ly da­ta from two tri­als for rare kid­ney dis­ease

A kid­ney-spe­cif­ic au­toim­mune dis­ease with no ap­proved ther­a­pies could face an op­po­nent in felzartam­ab, an in­ves­ti­ga­tion­al mon­o­clon­al an­ti­body, ac­cord­ing to its de­vel­op­er.

Da­ta from two ear­ly tri­als of the an­ti­body were re­leased to­day from Hu­man Im­munol­o­gy Bio­sciences (HI-Bio), which the com­pa­ny says shows pos­i­tive im­pact on pri­ma­ry mem­bra­nous nephropa­thy (PMN), a rare im­mune-me­di­at­ed dis­ease that im­pacts more than 36,000 peo­ple in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER